Skip to content
DataLookout
Menu

NCT07909733

Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Maximum tolerated dose (MTD) of imetelstat
Timeframe: 1 year

Secondary (5)

Incidence of adverse events
Rate of non-relapse mortality (NRM)
Rate of relapse
Progression-free survival (PFS)
Overall survival (OS)

Arms and interventions

Dose escalationExperimental

Participants will receive imetelstat intravenously every 4 weeks with dose escalation.

Drugs: imetelstat

Sites

1 site in 1 country

  • University of Wisconsin - MadisonMadison, Wisconsin, United States